GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

Do GLP-1 Drugs Reduce Cancer Risk or Increase It?

Emerging evidence links popular weight-loss drugs to lower cancer rates, but are these effects real, or simply a reflection of better metabolic health?

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

How Oral GLP-1 Drugs Work For Weight Loss

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Recent Advancements in Treatment for Parkinson’s Disease

What Are Advanced Glycation End Products and Why They Matter

The Natural Molecule That Could Rival Ozempic

The Unexpected Effects of GLP-1 Medications on Women’s Health

Top Nutrients and Habits That Boost GLP-1 Naturally

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

The Impact of Glucagon on Diabetes Management

Wegovy: A Breakthrough in Weight Loss?

See more featured articles »

Gut-Brain Axis and Obesity

How Does Semaglutide Work to Lose Weight?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

The Potential of Peptide Therapeutics in Treating Chronic Diseases

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Peptide Therapy: The Future of Targeted Treatment?

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Is Berberine Really “Nature’s Ozempic”? What Science Says

Multiple Endocrine Neoplasia Type 1 (MEN1)

The Future of Diabetes Treatment

Semaglutide and Weight Loss in Menopause

Latest GLP 1 Agonists News and Research

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

Experts outline a multidisciplinary approach to managing clinical obesity

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment.

17 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

GLP-1s may improve testosterone levels and sperm quality in men with obesity

GLP‑1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

15 Jun 2026

Study reveals frequent stop-and-start patterns with GLP-1 drugs

People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Injectable semaglutide may improve fertility outcomes in PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

9 Jun 2026

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

Weight loss medications show promise in preventing obesity-related cancers

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

7 Jun 2026

Why exercise matters for obesity even when the scale barely moves

AHA's scientific statement reveals exercise's vital role in obesity management, boosting cardiovascular health and supporting long-term weight loss efforts.

4 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Semaglutide boosts well-being among patients with diabetes and CKD

New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year.

3 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Existing drug mitigates muscle loss from GLP-1 medications

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss.

2 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026